Navigation Links
Cytos Biotechnology Ltd Announces the Completion of Patient Enrolment in the On-going Phase 2b Study of CYT003 for the Treatment of Allergic Asthma
Date:10/20/2013

ZURICH, October 21, 2013 /PRNewswire/ --

Cytos Biotechnology Ltd (SIX:CYTN) ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003. This study investigates the effectiveness, safety and tolerability of CYT003 in patients with moderate to severe allergic asthma not controlled on their standard treatment.

Based on the completion of the enrolment of this study, Cytos will call the second tranche of the convertible loan notes in the amount of CHF 6.625 million from Abingworth, venBio, Aisling and Amgen, which was part of the investment by this syndicate of investors in May 2012.

Dr. Christian Itin, Chairman and CEO of Cytos, said: "We are pleased with the progress of our Phase 2b study in patients with moderate to severe allergic asthma. The study is on track and we expect topline data from the study to be available in the second quarter of 2014."

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a novel, first-in-class, immune modulator in Phase 2 clinical development as a potential new treatment for asthma. CYT003 has a novel mechanism of action that inhibits the immune response that causes asthma, and may therefore be beneficial for the control of asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function in patients with persistent allergic asthma despite withdrawal of standard therapy with inhaled corticosteroids. CYT003 has been shown to have a good safety and tolerability profile in more than 450 individuals receiving the active agent so far.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

http://www.cytos.com

Forward looking statements  This foregoing press release may contain forward-looking statements that include words or phrases such as "would", "can", "expect", "are intended for", "are designed to", or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments.


'/>"/>
SOURCE Cytos Biotechnology Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytos Biotechnology Ltd Reports Second Quarter 2013 Financial Results and Recent Developments
2. Cytos Invites to the Annual Shareholders Meeting 2013
3. A*STAR and Cytos Bring Singapores First Influenza Vaccine to Clinical Testing
4. Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine
5. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
6. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
7. NextSource Biotechnology Launches New Strategic Approach to Mitigate Slow-Downs in Manufacturing of Matured Medications in High Demand
8. Goodwin Biotechnology Announces the Appointment of SooYoung S. Lee, PhD as Chief Operating Officer
9. Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship
10. TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States
11. The Galien Foundation Announces 2013 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... -- Compass Diversified Holdings (NYSE: CODI ) ("CODI," ... middle market businesses, announced today its consolidated operating results ... First Quarter 2016 Highlights , Generated Cash ... Flow") of $13.6 million for the first quarter of ... for the first quarter of 2016; , Paid ...
(Date:5/4/2016)... -- According to market research "Global Computed Tomography ... 2022 - Industry Insights by Slice Type (High, Mid and ... P&S Market Research, the global computed tomography market ... expected to grow at a CAGR of 5.0% during 2016-2022. ... expected to witness the faster growth, CAGR of 5.3%, during ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Multiple Myeloma Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Multiple Myeloma market valuations and forecast, ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... ... A recent survey by the Midwest Business Group on Health (MBGH) ... the free preventive care benefits available to them as part of the Affordable Care ... and private employers, MBGH found that only 10% of large employers are aware of ...
(Date:5/5/2016)... Dubuque, IA (PRWEB) , ... May 05, 2016 ... ... his insurance agency’s ongoing community enrichment program serving families of greater Dubuque, IA. ... area’s active duty, reserve and honorably discharged veterans. Donations to Veteran’s Freedom Center ...
(Date:5/5/2016)... ... May 05, 2016 , ... A ... found that more than 40 percent of participating fifth-grade students already have or ... Allergy and Asthma Clinical Research in the Division of Pulmonary, Allergy and Critical ...
(Date:5/5/2016)... YORK (PRWEB) , ... May 05, 2016 , ... TIME ... swimming safety – today announced a new partnership to reach nearly 1 million children ... happen in an instant and is the leading cause of accidental death in children ...
(Date:5/5/2016)... ARIZ. (PRWEB) , ... May 05, 2016 , ... ... president Jennifer Drago presented a talk highlighting the organization’s successful Care Transitions ... in Chicago. , The talk was titled “Minimizing Costs in the Post-Acute Environment ...
Breaking Medicine News(10 mins):